Wikipedia

Tumid lupus erythematosus

(Redirected from Lupus erythematosus tumidus)

Tumid lupus erythematosus is a rare, but distinctive entity in which patients present with edematous erythematous plaque.[2]

Tumid lupus erythematosus
Other names"Lupus erythematosus tumidus"[1]
SpecialtyDermatology

Lupus erythematosus tumidus (LET) was reported by Henri Gougerot and Burnier R. in 1930. It is a photosensitive skin disorder, a different subtype of cutaneous lupus erythematosus (CLE) from discoid lupus erythematosus (DLE) or subacute CLE (SCLE).[3] LET is usually found on sun-exposed areas of the body. Skin lesions are edematous, urticarialike annular papules and plaques. Topical corticosteroids are not effective as treatment for LET, but many will respond to chloroquine. LET resolves with normal skin, no residual scarring, no hyperpigmentation or hypopigmentation. Cigarette smokers who have LET may not respond very well to chloroquine.[4][5]

It has been suggested that it is equivalent to Jessner lymphocytic infiltrate of the skin.[6]

Signs and symptoms

edit

The characteristic presentation of tumid lupus erythematosus is erythematous, edematous plaques that lack ulceration or scaling.[4] In contrast to discoid lupus erythematosus (DLE), there is no atrophy, scarring, or follicular plugging. Skin exposed to the elements, such as the face, upper chest (V-neck distribution),  upper back, extensor arms, and shoulders, is typically affected by tumid lupus erythematosus.[7] Rare cases of tumid lupus erythematosus affecting the lower extremities have been documented, nevertheless.[8] Tumid lupus erythematosus typically manifests itself in the summer in temperate climates.[7]

Papules and plaques of tumid lupus erythematosus can create an annular pattern in certain patients, resembling annular subacute cutaneous lupus erythematosus (SCLE), with less edema at the center. A Blaschkoid distribution,[9][10] scalp involvement resembling alopecia areata,[11] and periorbital edema are less frequent signs of tumid lupus erythematosus.[12]

Causes

edit

There is currently no known unique etiology for tumid lupus erythematosus. However, it has been shown that triggering variables like ultraviolet (UV) exposure can exacerbate tumid lupus erythematosus lesions.[13] Its link to autoimmune disease has generated debate; an autoimmune workup may be started if an autoimmune disease is suspected.[14][15] It is suggested that immune dysregulation results in T cell suppression.[16] There has been evidence of a correlation between smoking and medications such as thiazide diuretics, monoclonal antibodies, angiotensin-converting enzyme inhibitors, tumor necrosis factor antagonists, and highly active antiretroviral therapy.[17][18]

Diagnosis

edit

The identification of consistent clinical symptoms and histopathologic findings is the basis for the diagnosis of tumid lupus erythematosus. Provocative phototesting results and antimalarial medication response are additional tests that are not usually required but can confirm a diagnosis of tumid lupus erythematosus.[7]

Proposed diagnostic criteria reflect key findings in tumid lupus erythematosus:[4]

  1. Clinical - Smooth-surfaced, succulent, urticarial-like, erythematous plaques in sun-exposed areas.[4]
  2. Histologic - There is no epidermal involvement or modification of the dermoepidermal interface; instead, there is perivascular and periadnexal lymphocytic infiltration, interstitial mucin deposition, and, in certain instances, dispersed neutrophils.[4]
  3. Phototesting - Skin lesion proliferation following exposure to ultraviolet A (UVA) and/or ultraviolet B (UVB) radiation.[4]
  4. Treatment - Quick and efficient systemic antimalarial medication treatment.[4]

Treatment

edit

First-line treatments include photoprotection, topical calcineurin inhibitors, and intralesional and/or topical corticosteroids. Antimalarial medications like hydroxychloroquine or chloroquine should be used as part of a systemic treatment for patients who do not respond to conservative therapy or who have a severe illness. Methotrexate or mycophenolate mofetil along with folic acid supplements are examples of second-line therapy.[19] If all previous treatments are ineffective, third-line treatments such as thalidomide or lenalidomide may be considered.[4][20] Another effective treatment for suppressive, non-curative conditions is pulse dye laser.[21] In order to keep the lesions from relapsing in these patients, trigger avoidance measures including wearing sunscreen and abstaining from smoking are essential.[19]

See also

edit

References

edit
  1. ^ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
  2. ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. Page 159. ISBN 0-7216-2921-0.
  3. ^ Gougerot H, Burnier R. Lupus érythémateux "tumidus". Bull Soc Fr Dermatol Syphiligr. 1930;37:1291-1292.
  4. ^ a b c d e f g h Kuhn, Annegret; Richter-Hintz, Dagmar; Oslislo, Claudia; Ruzicka, Thomas; Megahed, Mosaad; Lehmann, Percy (2000-08-01). "Lupus Erythematosus Tumidus". Archives of Dermatology. 136 (8). American Medical Association (AMA): 1033–1041. doi:10.1001/archderm.136.8.1033. ISSN 0003-987X. PMID 10926740.
  5. ^ Callen, Jeffrey P. (2002). "Management of skin disease in patients with lupus erythematosus". Best Practice & Research Clinical Rheumatology. 16 (2). Elsevier BV: 245–264. doi:10.1053/berh.2001.0224. ISSN 1521-6942. PMID 12041952.
  6. ^ "Jessner Lymphocytic Infiltration of the Skin: eMedicine Dermatology". Retrieved 2010-05-22.
  7. ^ a b c "UpToDate". UpToDate. Retrieved 2024-03-02.
  8. ^ Stead, Jennifer; Headley, Catherine; Ioffreda, Michael; Kovarik, Carrie; Werth, Victoria (2008). "Coexistence of Tumid Lupus Erythematosus With Systemic Lupus Erythematosus and Discoid Lupus Erythematosus". JCR: Journal of Clinical Rheumatology. 14 (6). Ovid Technologies (Wolters Kluwer Health): 338–341. doi:10.1097/rhu.0b013e31817d1183. ISSN 1076-1608. PMC 2829660. PMID 18664992.
  9. ^ Pacheco, T R; Spates, S T; Lee, L A (2002). "Unilateral tumid lupus erythematosus". Lupus. 11 (6). SAGE Publications: 388–391. doi:10.1191/0961203302lu208cr. ISSN 0961-2033. PMID 12139378. S2CID 35133682.
  10. ^ Hinz, Torsten; Hornung, Thorsten; Wenzel, Joerg; Bieber, Thomas (2012-03-27). "Lupus tumidus following the lines of Blaschko". International Journal of Dermatology. 52 (12). Wiley: 1615–1617. doi:10.1111/j.1365-4632.2011.05419.x. ISSN 0011-9059. PMID 22458246. S2CID 27225913.
  11. ^ Werth, Victoria P. (1992-03-01). "Incidence of Alopecia Areata in Lupus Erythematosus". Archives of Dermatology. 128 (3): 368. doi:10.1001/archderm.1992.01680130082010. ISSN 0003-987X. PMID 1550369.
  12. ^ Vassallo, Camilla; Colombo, Giovanni; Canevari, Frank Rikki; Brazzelli, Valeria; Ardigò, Marco; Carrera, Carlo; Cananzi, Raffaello; Borroni, Giovanni (2005-04-14). "Monolateral severe eyelid erythema and edema as unique manifestation of lupus tumidus". International Journal of Dermatology. 44 (10). Wiley: 858–860. doi:10.1111/j.1365-4632.2005.02210.x. ISSN 0011-9059. PMID 16207190. S2CID 45610534.
  13. ^ Saleh, Dahlia; Grubbs, Hailey; Koritala, Thoyaja; Crane, Jonathan S. (2023-06-28). "Tumid Lupus Erythematosus". StatPearls Publishing. PMID 29494121. Retrieved 2024-03-02.
  14. ^ Jefferson, Gina D.; Aakalu, Vinay K.; Braniecki, Marylee (2017). "Tumid lupus: An unexpected diagnosis for the otolaryngologist". American Journal of Otolaryngology. 38 (2). Elsevier BV: 257–259. doi:10.1016/j.amjoto.2017.01.003. ISSN 0196-0709. PMC 5826658. PMID 28122678.
  15. ^ Fogagnolo, L.; Soares, T. C. B.; Senna, C. G.; Souza, E. M.; Blotta, M. H. S. L.; Cintra, M. L. (2014-09-12). "Cytotoxic granules in distinct subsets of cutaneous lupus erythematosus". Clinical and Experimental Dermatology. 39 (7). Oxford University Press (OUP): 835–839. doi:10.1111/ced.12428. ISSN 0307-6938. PMID 25214407. S2CID 21127920.
  16. ^ Gambichler, T.; Pätzholz, J.; Schmitz, L.; Lahner, N.; Kreuter, A. (2015-03-25). "<scp>FOXP</scp>3+ and <scp>CD</scp>39+ regulatory T cells in subtypes of cutaneous lupus erythematosus". Journal of the European Academy of Dermatology and Venereology. 29 (10). Wiley: 1972–1977. doi:10.1111/jdv.13123. ISSN 0926-9959. PMID 25808110. S2CID 30625226.
  17. ^ Böckle, B C; Sepp, N T (2014-11-19). "Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients". Lupus. 24 (7). SAGE Publications: 669–674. doi:10.1177/0961203314559630. ISSN 0961-2033. PMID 25411260. S2CID 43483915.
  18. ^ Schneider, Stefan W.; Staender, Sonja; Schlüter, Bernhard; Luger, Thomas A.; Bonsmann, Gisela (2006-01-01). "Infliximab-Induced Lupus Erythematosus Tumidus in a Patient With Rheumatoid Arthritis". Archives of Dermatology. 142 (1). American Medical Association (AMA): 115–116. doi:10.1001/archderm.142.1.115. ISSN 0003-987X. PMID 16415403.
  19. ^ a b Liu, Evan; Daze, Robert P; Moon, Summer (2020-05-26). "Tumid Lupus Erythematosus: A Rare and Distinctive Variant of Cutaneous Lupus Erythematosus Masquerading as Urticarial Vasculitis". Cureus. Springer Science and Business Media LLC. doi:10.7759/cureus.8305. ISSN 2168-8184. PMC 7320659. PMID 32607289.
  20. ^ Gallitano, Stephanie M.; Haskin, Alessandra (2016). "Lupus erythematosus tumidus: A case and discussion of a rare entity in black patients". JAAD Case Reports. 2 (6). Elsevier BV: 488–490. doi:10.1016/j.jdcr.2016.05.022. ISSN 2352-5126. PMC 5149049. PMID 27981226.
  21. ^ Truchuelo, M.T.; Boixeda, P.; Alcántara, J.; Moreno, C.; de las Heras, E.; Olasolo, P.J. (2012). "Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study". Journal of the European Academy of Dermatology and Venereology. 26 (10): 1272–1279. doi:10.1111/j.1468-3083.2011.04281.x. ISSN 0926-9959. PMID 21957901.

Further reading

edit
  • Schmitt, V.; Meuth, A.M.; Amler, S.; Kuehn, E.; Haust, M.; Messer, G.; Bekou, V.; Sauerland, C.; Metze, D.; Köpcke, W.; Bonsmann, G.; Kuhn, A. (2009-07-07). "Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus". British Journal of Dermatology. 162 (1). Oxford University Press (OUP): 64–73. doi:10.1111/j.1365-2133.2009.09401.x. ISSN 0007-0963. PMID 19712116. S2CID 23655462.
  • Vieira, Vanessa; Del Pozo, Jesús; Yebra-Pimentel, Maria Teresa; Martínez, Walter; Fonseca, Eduardo (2005-01-06). "Lupus erythematosus tumidus: a series of 26 cases". International Journal of Dermatology. 45 (5). Wiley: 512–517. doi:10.1111/j.1365-4632.2004.02574.x. ISSN 0011-9059. PMID 16700782. S2CID 43363996.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tumid_lupus_erythematosus&oldid=1229851506"